The relentless path of SARS-CoV-2 serves as one example of the sharp refocusing of our attention on biotechnology and programmable medicines. Digital biology is now driving the biotech industry, redefining its approach to vaccine development and our understanding both illness and disease. What impact will this new approach have on changing the paradigm?